Join us in Bucharest! Sharing vipoglanstat's potential for better endometriosis treatment

We look forward to present a poster on vipoglanstat at the upcoming European Endometriosis Congress in Bucharest.

"Vipoglanstat, a non-hormonal treatment for endometriosis ready to start phase II"

Vipoglanstat has demonstrated excellent pain-relieving effects in several preclinical inflammatory pain models, including an endometriosis disease model. Together with outstanding safety and tolerability at doses achieving full inhibition of its target enzyme, this paves the way for phase II development for endometriosis.

EEC 2024 will be an excellent opportunity to connect with colleagues, share insights, and explore potential collaborations.

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.